Analysts Issue Forecasts for INSP Q3 Earnings

Key Points

• Inspire Medical Systems is expected to earn $0.25 per share for Q3 2025, according to analysts at KeyCorp, who also estimate full-year earnings of $2.16 per share.
• The company reported a quarterly EPS of $0.45, surpassing expectations of $0.22, with a revenue of $217.09 million, a 10.8% increase year-over-year.
• Recent analyst ratings show a diverse outlook on the stock, with target prices ranging from $101.00 to $236.00 and an average rating of "Moderate Buy" among 14 analysts.

Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) - Analysts at KeyCorp issued their Q3 2025 earnings per share estimates for Inspire Medical Systems in a report issued on Monday, August 4th. KeyCorp analyst B. Fishbin forecasts that the company will post earnings of $0.25 per share for the quarter. KeyCorp has a "Sector Weight" rating on the stock. The consensus estimate for Inspire Medical Systems' current full-year earnings is $2.16 per share. KeyCorp also issued estimates for Inspire Medical Systems' Q4 2025 earnings at $0.84 EPS, FY2025 earnings at $1.64 EPS and FY2026 earnings at $1.69 EPS.

Other equities research analysts also recently issued research reports about the company. Truist Financial reaffirmed a "hold" rating and issued a $125.00 price objective (down previously from $190.00) on shares of Inspire Medical Systems in a research report on Tuesday, August 5th. UBS Group cut their price target on Inspire Medical Systems from $270.00 to $230.00 and set a "buy" rating on the stock in a research note on Tuesday, August 5th. Piper Sandler cut their price objective on Inspire Medical Systems from $233.00 to $150.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. JPMorgan Chase & Co. cut Inspire Medical Systems from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $195.00 to $110.00 in a research note on Tuesday, August 5th. Finally, Robert W. Baird upped their price objective on Inspire Medical Systems from $230.00 to $236.00 and gave the company an "outperform" rating in a research note on Tuesday, May 6th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Inspire Medical Systems currently has an average rating of "Moderate Buy" and an average price target of $173.31.

Inspire Medical Systems Trading Down 0.8%

Shares of NYSE INSP traded down $0.62 during trading on Thursday, reaching $78.52. The company had a trading volume of 619,972 shares, compared to its average volume of 659,217. The stock has a market capitalization of $2.32 billion, a PE ratio of 45.39, a price-to-earnings-growth ratio of 2.44 and a beta of 1.22. Inspire Medical Systems has a twelve month low of $73.92 and a twelve month high of $225.00. The stock has a 50-day moving average price of $126.77 and a two-hundred day moving average price of $151.38.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.23. The firm had revenue of $217.09 million during the quarter, compared to analysts' expectations of $214.50 million. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%. Inspire Medical Systems's revenue was up 10.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 earnings per share.

Institutional Investors Weigh In On Inspire Medical Systems

A number of institutional investors and hedge funds have recently modified their holdings of INSP. Parallel Advisors LLC lifted its position in shares of Inspire Medical Systems by 356.5% during the 1st quarter. Parallel Advisors LLC now owns 210 shares of the company's stock valued at $33,000 after acquiring an additional 164 shares during the last quarter. True Wealth Design LLC increased its position in Inspire Medical Systems by 39.0% during the fourth quarter. True Wealth Design LLC now owns 196 shares of the company's stock worth $36,000 after buying an additional 55 shares during the last quarter. Quarry LP grew its position in shares of Inspire Medical Systems by 2,127.3% in the first quarter. Quarry LP now owns 245 shares of the company's stock valued at $39,000 after purchasing an additional 234 shares during the last quarter. Banque Transatlantique SA acquired a new stake in shares of Inspire Medical Systems in the first quarter valued at about $46,000. Finally, Quadrant Capital Group LLC grew its position in shares of Inspire Medical Systems by 61.9% in the fourth quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock valued at $61,000 after purchasing an additional 125 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.